Daiwa Securities Group
LGND icon

Daiwa Securities Group’s Ligand Pharmaceuticals LGND Stock Holding History

Daiwa Securities Group’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-160
Closed -$17K – 1189
2019
Q2 		$17K Hold
160
– – ﹤0.01% 1021
2019
Q1 		$17K Buy
+160
New +$12.1K ﹤0.01% 998

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Daiwa Securities Group's LGND Position: Q1 2026 in Review

Daiwa Securities Group sold out of Ligand Pharmaceuticals (LGND) in Q1 2026, closing a stake of 58 shares — an estimated $11K sold.

Daiwa Securities Group first reported a position in LGND in Q1 2018 and held it in 32 quarters. The position peaked at $32K in Q3 2018. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Daiwa Securities Group reported no remaining Ligand Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Daiwa Securities Group sold 58 Ligand Pharmaceuticals shares in Q1 2026, an estimated $11K.
  • Daiwa Securities Group first reported a position in Ligand Pharmaceuticals in Q1 2018 and held it in 32 quarters.
  • Daiwa Securities Group's Ligand Pharmaceuticals position peaked at $32K in Q3 2018.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.